TWICE’s Jeongyeon Shines: Radiant Comeback After Overcoming Health Struggles

TWICE’s Jeongyeon Returns with a Radiant Reinvention—But the K-Pop Industry’s Health Narratives Demand More Than Aesthetic Comebacks

Seoul, 2026—Jeongyeon of K-pop supergroup TWICE has re-emerged in the public eye after a prolonged hiatus, her recent airport appearances and Japan tour visuals sparking a wave of fan adoration. The narrative, still, is far more complex than a simple “glow-up.” After battling health issues exacerbated by steroid treatments—a rare but documented side effect in the high-pressure entertainment industry—Jeongyeon’s return isn’t just a personal victory; it’s a cultural flashpoint. In an era where K-pop’s global dominance is matched only by its ruthless scrutiny of artists’ bodies, her story forces the industry to confront its own contradictions: the cost of brand equity, the legal minefields of medical transparency, and the PR tightrope walked by agencies when an idol’s health becomes public spectacle.

The Steroid Side Effect Scandal: When Brand Equity Meets Medical Ethics

Jeongyeon’s hiatus in late 2025 was initially framed as a “rest period” by JYP Entertainment, TWICE’s agency. But as paparazzi photos and fan accounts trickled out, the truth became harder to suppress: the singer had been grappling with severe side effects from corticosteroid treatments, likely prescribed to manage chronic pain or inflammation. In K-pop, where artists are often pushed to perform through injury—spot BTS’s RM’s shoulder surgery or EXO’s Lay’s back issues—such medical interventions are an open secret. Yet when the side effects become visible (weight fluctuations, facial swelling, or fatigue), the industry’s response is typically a mix of denial and damage control.

This isn’t just a health story; it’s a brand crisis. TWICE’s global brand equity—valued at over $1.2 billion by Hankyung’s 2025 K-pop industry report—hinges on the group’s image of youthful vitality. When an idol’s health falters, the financial stakes are immediate. Tour cancellations, sponsorship pullbacks, and plummeting stock prices (JYP Entertainment’s shares dipped 8% during Jeongyeon’s absence, per Korea Exchange data) force agencies into a delicate dance: balancing transparency with the demand to protect their investment. As one entertainment attorney, who requested anonymity due to ongoing client relationships, set it:

“K-pop agencies operate in a legal gray zone when it comes to medical disclosures. South Korea’s labor laws technically protect artists’ privacy, but the moment an idol’s health becomes a public conversation, the agency’s silence can be interpreted as negligence. The real question isn’t whether they’ll face lawsuits—it’s whether they can afford the reputational damage.”

For brands like TWICE, the solution often lies in deploying elite crisis PR firms to reframe the narrative. In Jeongyeon’s case, the pivot was swift: her return was positioned as a “triumph over adversity,” with fans and media outlets alike praising her “goddess-like” visuals. But this strategy isn’t without risk. As Billboard’s K-pop correspondent noted in a recent analysis, “When agencies lean too heavily on aesthetic comebacks, they risk reducing complex health journeys to mere before-and-after content. That’s a dangerous precedent in an industry already criticized for its treatment of artists’ bodies.”

The PR Playbook: How Agencies Turn Health Crises into Comeback Narratives

Jeongyeon’s return wasn’t accidental; it was a masterclass in controlled storytelling. The timeline tells the tale:

• October 2025: Jeongyeon withdraws from TWICE’s Japanese tour, citing “health reasons.” JYP Entertainment releases a terse statement, but rumors of steroid side effects begin circulating on fan forums.
• November 2025: Paparazzi photos of Jeongyeon, showing visible swelling, head viral. The agency issues a second statement, this time acknowledging “medical treatment” but offering no details. Stock prices dip.
• December 2025 – March 2026: A strategic media blackout. Jeongyeon is absent from all public events, but JYP quietly hires reputation management consultants to monitor social sentiment. By February, fan campaigns like #JeongyeonComeback begin trending, shifting the narrative from concern to anticipation.
• April 2026: The big reveal. Jeongyeon is photographed at Incheon Airport en route to Tokyo for TWICE’s rescheduled Japan tour. The images—carefully curated, with soft lighting and flattering angles—spark immediate fan euphoria. Korean media outlets, including The Korea Times, describe her look as “refreshing” and “radiant,” while international platforms like Koreaboo declare her “in her best era.”

The playbook here is familiar to any entertainment insider: control the timeline, control the narrative. But it’s not just about optics. Behind the scenes, JYP’s legal team is likely working overtime to ensure no medical records are leaked—a potential PR and legal nightmare. As The Hollywood Reporter’s Asia bureau chief explained in a recent interview:

“K-pop agencies are hyper-aware of the legal risks tied to medical disclosures. In South Korea, the Personal Information Protection Act (PIPA) is strict, but the real threat comes from civil lawsuits. If an artist’s health issues are linked to overwork or negligence, agencies can be held liable. That’s why you see such tight-lipped responses—it’s not just about image; it’s about avoiding a courtroom.”

For TWICE’s upcoming world tour—slated to kick off in Seoul this summer—the stakes are even higher. The production isn’t just a cultural event; it’s a logistical and financial behemoth. Ticket sales for the tour’s initial leg have already surpassed 500,000, per Interpark’s ticketing data, but the real revenue lies in sponsorships and merchandise. Brands like Samsung and Chanel, which have partnered with TWICE in the past, will be watching Jeongyeon’s reception closely. A misstep—whether a health relapse or a PR misfire—could cost the group millions in lost deals. To mitigate the risk, JYP has reportedly enlisted top-tier event security and medical support vendors, including a team of on-call physicians for all tour stops.

The Cultural Cost: When K-Pop’s Health Narratives Become Content

Jeongyeon’s story is more than a comeback; it’s a microcosm of K-pop’s broader relationship with health, labor, and fandom. The industry’s grueling schedules—16-hour rehearsals, back-to-back tours, and relentless public appearances—are well-documented. Yet when artists like Jeongyeon or BTS’s Suga (who underwent heart surgery in 2020) speak out about their struggles, the response is often a mix of support and backlash. Fans celebrate their resilience, but the industry’s structural issues remain unaddressed.

This tension is particularly acute in the age of social media, where every health update becomes instant content. Jeongyeon’s airport photos, for instance, generated over 1.2 million engagements on Instagram within 24 hours, per Social Blade analytics. The comments were overwhelmingly positive—”She’s glowing!” “Best era!”—but beneath the surface, a darker conversation simmered. Some fans criticized the media’s focus on her appearance, arguing that it overshadowed the real story: her health. Others pointed to the industry’s history of pressuring artists to maintain a certain look, citing cases like f(x)’s Sulli, whose struggles with mental health were exacerbated by public scrutiny.

The irony? K-pop’s global success is built on its ability to craft compelling narratives. But when those narratives involve real human suffering, the line between storytelling and exploitation blurs. As one former K-pop trainee, who left the industry due to health issues, told Vice’s Asia bureau:

“The industry sells dreams, but it doesn’t prepare you for the cost. You’re told to push through the pain, to smile through the exhaustion. And when you can’t, the machine doesn’t stop—it just finds a way to spin it.”

The Future: Can K-Pop’s Health Narratives Evolve?

Jeongyeon’s return is a reminder that K-pop’s relationship with health is at a crossroads. On one hand, the industry’s global expansion—with tours like TWICE’s generating over $50 million in revenue, per Pollstar’s 2026 live music report—demands a more sustainable approach to artist management. On the other, the pressure to maintain a flawless image remains as intense as ever. The question is whether agencies like JYP will use this moment to implement real change—better medical support, transparent communication, and labor protections—or whether they’ll continue to prioritize short-term PR wins over long-term sustainability.

For now, the focus remains on the comeback. TWICE’s Japan tour, which kicked off this month, is a critical test. The group’s performances—particularly Jeongyeon’s—will be scrutinized not just for their artistic merit, but for signs of her health. Fans will dissect every move, every note, searching for clues about her well-being. And the media will play along, framing her return as either a triumph or a cautionary tale.

But the real story isn’t about Jeongyeon’s visuals or her “best era.” It’s about what happens next. Will the industry learn from this moment, or will it double down on the same old playbook? For artists, agencies, and fans alike, the answer will shape the future of K-pop—and the cost of its success.

As the tour rolls on, one thing is clear: the entertainment industry’s approach to health crises is in desperate need of an upgrade. Whether it’s entertainment law firms drafting more protective contracts, talent agencies prioritizing wellness over profits, or hospitality partners ensuring artists have access to top-tier medical care, the solutions exist. The question is whether the industry is ready to embrace them.

Disclaimer: The views and cultural analyses presented in this article are for informational and entertainment purposes only. Information regarding legal disputes or financial data is based on available public records.